索乐普尼治疗原发性或继发性温抗体型自身免疫性溶血性贫血:随机双盲安慰剂对照2/3期研究2期结果
这项在中国13个中心开展的随机双盲安慰剂对照2/3期研究的2期部分,纳入21例糖皮质激素无效的温抗体型自身免疫性溶血性贫血患者,按3:1随机接受索乐普尼300 mg每日一次或安慰剂治疗8周,随后开放标签治疗至24周。24周时总体血红蛋白缓解率为67%(14/21),持续缓解率为48%(10/21);索乐普尼耐受性良好,3期部分正在进行。
要点
- 24周时总体血红蛋白缓解率为67%(14/21),持续血红蛋白缓解率为48%(10/21)。
- 双盲期索乐普尼组13/16例(81%)报告治疗中出现的不良事件,安慰剂组5/5例(100%)。
- 24周索乐普尼治疗期间仅7例(33%)出现3级事件,最常见3级不良事件为贫血(4例,19%),与治疗无关。
核心结论
- 索乐普尼在中国温抗体型自身免疫性溶血性贫血患者中取得令人鼓舞的总体血红蛋白缓解,且耐受性良好。
- 研究的3期部分(ESLIM-02)正在进行,以进一步证实索乐普尼在该领域的疗效和安全性。
研究设计与样本
- 研究为随机、双盲、安慰剂对照的2/3期研究的2期部分,在中国13个中心开展。
- 纳入18-75岁、ECOG体能状态不超过2分、原发性或继发性温抗体型自身免疫性溶血性贫血(基础疾病稳定且不需药物干预)、既往糖皮质激素治疗无效、血红蛋白低于100 g/L伴活动性溶血、直接抗人球蛋白试验阳性的患者。
- 患者按3:1随机分配至索乐普尼300 mg口服每日一次或安慰剂,双盲治疗8周,随后全部进入开放标签治疗期至少16周,接受索乐普尼300 mg每日一次至末例患者随机分配后24周。
- 2期主要终点为第24周时的总体血红蛋白缓解率(血红蛋白≥100 g/L且较基线升高≥20 g/L至少一次,且血红蛋白未受输血、静脉注射免疫球蛋白和糖皮质激素等补救治疗影响)。
- 双盲期0-8周疗效分析纳入所有随机分配患者,按意向性治疗分析;安全性分析纳入意向性治疗人群中至少接受一剂研究药物的患者。
主要发现
- 2022年9月26日至2023年5月9日期间筛查34例患者,21例(男性4例[19%],女性17例[81%])入组并随机分配至索乐普尼组(n=16)或安慰剂组(n=5)。
- 全部21例患者完成0-8周双盲治疗并进入开放标签治疗期。
- 第24周时总体血红蛋白缓解率为67%(14/21),持续血红蛋白缓解率为48%(10/21)。
- 0-8周双盲治疗期间,索乐普尼组16例中13例(81%)报告治疗中出现的不良事件,安慰剂组5例中5例(100%)报告。
- 0-8周双盲治疗期间,索乐普尼组16例中4例(25%)报告3级不良事件,安慰剂组5例中4例(80%)报告。
关键数值与推荐
- 总体血红蛋白缓解定义:血红蛋白≥100 g/L且较基线升高≥20 g/L至少一次,且血红蛋白未受补救治疗(如红细胞输注、静脉注射免疫球蛋白和糖皮质激素)影响。
- 双盲期索乐普尼剂量为300 mg口服每日一次,开放标签期索乐普尼剂量为300 mg口服每日一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spleen tyrosine kinase inhibitors are potential treatment options for warm autoimmune haemolytic anaemia. This study aimed to assess the preliminary efficacy and safety of sovleplenib-an oral spleen tyrosine kinase inhibitor-in patients with warm autoimmune haemolytic anaemia in China. Here we report on the phase 2 results. METHODS: This randomised, double-blind, placebo-controlled, phase 2 part from the phase 2/3 study was conducted at 13 centres in China. Eligible patients, aged 18-75 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of no more than 2, had primary or secondary warm autoimmune haemolytic anaemia (stable underlying disease not requiring drug intervention) with no response to previous glucocorticoid treatment, haemoglobin of less than 100 g/L with active haemolysis, and a positive direct antiglobulin test. The study comprised two periods; patients were randomly assigned (3:1) to receive sovleplenib or placebo at 300 mg orally once a day in the 8-week double-blind period. Upon completion, all patients entered an open-label treatment period for at least 16 weeks and received sovleplenib 300 mg once a day until 24 weeks after the last patient was randomly assigned. The primary endpoint for phase 2 of the trial was overall haemoglobin response rate (haemoglobin ≥100 g/L with an increase of ≥20 g/L from baseline at least once, and haemoglobin not affected by rescue therapy, such as red blood cell transfusions, intravenous immunoglobulin, and glucocorticoids) by week 24. Efficacy analyses in the 0-8 week double-blind period included all patients who were randomly assigned, analysed by intention-to-treat. Safety analysis in the double-blind period included patients in the intention-to-treat population who received at least one dose of the study medication. This phase 2/3 study is registered with ClinicalTrials.gov, NCT05535933, and the phase 3 part is ongoing. FINDINGS: Between Sept 26, 2022, and May 9, 2023, 34 patients were screened and 21 patients (four [19%] male and 17 [81%] female) were enrolled in the study and randomly assigned to receive either sovleplenib (n=16) or placebo (n=5). All 21 patients completed the 0-8-week double-blind treatment and entered the open-label treatment period. The overall haemoglobin response rate was 67% (14 of 21 patients) by week 24, and durable haemoglobin response rate was 48% (ten of 21 patients) by week 24. During the 0-8-week double-blind treatment, 13 (81%) of 16 patients in the sovleplenib group versus five (100%) of five patients taking placebo reported treatment-emergent adverse events (TEAEs), and four (25%) of 16 patients versus four (80%) of five patients reported grade 3 adverse events. Although all 21 patients had a TEAE during the 24-week treatment with sovleplenib, only seven (33%) patients had grade 3 events. The most common grade 3 TEAE was anaemia (four [19%] patients), which was not related to treatment. There were no grade 4 or 5 TEAEs. INTERPRETATION: Sovleplenib treatment achieved an encouraging overall haemoglobin response in Chinese patients with warm autoimmune haemolytic anaemia and was well tolerated. The phase 3 part of the study (ESLIM-02) is currently ongoing to further substantiate the efficacy and safety of sovleplenib in this setting. FUNDING: HUTCHMED.
引用
- Zhao X, Sun J, Zhang Z, et al. Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study. Lancet Haematol. 2025. PMID: 39799953. doi:10.1016/S2352-3026(24)00344-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。